

Wei-Kuang has over 30 years' experience in biotechnology process development. He established DCB's multi-product 500 L mammalian cell culture and 100 L microbial fermentation CGMP Biopharmaceutical Pilot Plant Facility (BPPF) and certified by Taiwan Department of Health (DOH) on December 2005 and received DMF with USA FDA on March 2006. The CGMP BPPF has been spun-off in 2013 to provide CDMO service on a broader scale.

His new responsibility will focus on new drug R&D, international collaboration, novel bioengineering technology, CAR-T/iPSC development, application of deep learning/AI on drug discovery and /biomanufacturing process. Wei-Kuang obtained his M.S in Engineering and Ph.D. in Chemical Engineering from the University of Pennsylvania, Philadelphia, USA.